The World Health Organization (WHO) said on Friday that it had had a very good dialogue with the developers of a second Russian candidate vaccine against COVID-19. “We can only have a position on a vaccine when we see the results of phase III clinical trials,” said WHO chief scientist Soumya Swaminathan at a news conference in Geneva.
Russia registered its second coronavirus vaccine on October 14. Developed by Vector’s State Virology and Biotechnology Research Center, the EpiVacCorona vaccine completed its early-stage human trials last month. The Vector Research Center obtained permission from the Russian Ministry of Health to conduct clinical trials of its vaccine on volunteers in July. The first volunteer was injected with the vaccine on July 27. The final group of 20 volunteers was discharged from the medical center on Sept. 8, according to the TASS report.
“Clinical trials have been very successful. Volunteers are developing the necessary titers and no one has any clinical signs after the vaccine, no temperature, or any other reaction,” said Anna Popova, Russia’s chief medical officer.
The drugmaker will begin Phase III trials in November-December. About 30,000 volunteers will participate in post-registration trials of the coronavirus vaccine, the press service of the Federal Surveillance Service for the Protection of Consumer Rights and Human Welfare said. TASS. The vaccine will be manufactured at the Vector Research Center industrial site.
“After registration, clinical trials involving volunteers from the age group over 60 and those with chronic diseases are planned, as well as placebo-controlled post-registration clinical trials involving 5,000 adult volunteers of different age groups. “, he explained the press service of the sanitary guard dog, according to TASS.
Russia had approved a COVID-19 vaccine, called Sputnik V, in August even before its final test. The vaccine is currently undergoing final trials in Russia on around 40,000 subjects. Sputnik V has been developed by the Gamaleya National Research Center for Epidemiology and Microbiology and RDIF.
.
